Fig. 2: Mutation profiles of BRAF-mutant appendiceal adenocarcinoma (AA) and colorectal cancer (CRC). | npj Precision Oncology

Fig. 2: Mutation profiles of BRAF-mutant appendiceal adenocarcinoma (AA) and colorectal cancer (CRC).

From: BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy

Fig. 2: Mutation profiles of BRAF-mutant appendiceal adenocarcinoma (AA) and colorectal cancer (CRC).The alternative text for this image may have been generated using AI.

A Oncoprint plot of the mutation profile of BRAFV600E AA. Bar charts display relative proportion of tumors with mutations in a given gene (red), wildtype (black), or were untested (light gray). B Oncoprint plot of the mutation profile of aBRAF AA. C Comparison of KRAS comutation in BRAFWT (gray) vs. BRAFV600E (blue) vs. aBRAF (skyblue) AA and CRC. D Comparison of TP53 comutation in BRAFWT (gray) vs. BRAFV600E (blue) vs. aBRAF (skyblue) AA and CRC. E Comparison of GNAS comutation in BRAFWT (gray) vs. BRAFV600E (blue) vs. aBRAF (skyblue) AA and CRC. P value by Pearson’s Chi-Squared. *, <0.05; **, <0.01; ***, <0.001; ****, <0.0001. No comparison shown within cancers = not significant.

Back to article page